Is Relmada Therapeutics Inc (RLMD) overvalued? · $692.3M cap
Relmada Therapeutics Inc (RLMD) is a biotechnology company listed on NASDAQ.
This page asks whether Relmada Therapeutics Inc (RLMD) looks expensive on cached numbers — not a short thesis.
No cached income statement for RLMD, so there is no earnings base to call rich or cheap.
RLMD currently screens at market cap $692.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RLMD 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RLMD stock page for the full model, not this heading.
Not investment advice.